The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

BACKGROUND: Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. AIM: The aim of this study was to explore the safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Rucker, James J, Marwood, Lindsey, Ajantaival, Riikka-Liisa J, Bird, Catherine, Eriksson, Hans, Harrison, John, Lennard-Jones, Molly, Mistry, Sunil, Saldarini, Francesco, Stansfield, Susan, Tai, Sara J, Williams, Sam, Weston, Neil, Malievskaia, Ekaterina, Young, Allan H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801675/
https://www.ncbi.nlm.nih.gov/pubmed/35090363
http://dx.doi.org/10.1177/02698811211064720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801675/
https://www.ncbi.nlm.nih.gov/pubmed/35090363
http://dx.doi.org/10.1177/02698811211064720

Ejemplares similares